News Headlines Article

Patients squeezed in Gilead, insurer showdown over costly hep C drugs
San Francisco Business Times

In a continuing fight with insurers centering on the cost of its groundbreaking hepatitis C drugs, Gilead Sciences Inc. will limit enrollment in its payment-assistance program by patients whose insurance companies limit coverage or don’t pay for the drugs at all. The program, like those set up by many other drug makers, is designed to help U.S. patients with high insurance co-pays or those whose insurers don’t fully cover Foster City-based Gilead’s (NASDAQ: GILD) Sovaldi and Harvoni.